

CSD/BSE&NSE/BM/2025-26
February 12, 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Investor Presentation

Please find annexed investor presentation on the unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Himanshu Agarwal
Whole-time Director and Chief Financial Officer
DIN: 06672915

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Cohance



INVESTOR PRESENTATION

Q3 and 9M FY26

FEBRUARY 12, 2026

This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to media or reproduced in any form, without prior written consent Cohance Lifesciences.

This document is based on information obtained from public sources and sources believed to be reliable and information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates.

Under no circumstances shall Cohance Lifesciences or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the content or any use thereof.



Executive summary

04

Business wise Strategy

15

**Business and Financial
performance**

07

Annexure

26

EXECUTIVE SUMMARY



Key Highlights 9MFY26

- FY26 represents a transition and bottoming phase, driven by portfolio mix changes, customer-led inventory normalisation, and timing shifts across select programmes
- FY26 revenue guidance is revised to an early-to-mid double-digit decline, reflecting incremental timing effects vs earlier flat outlook
- Leadership appointment completed; upgraded functional depth across BD, Quality, Regulatory, R&D and Operations
- Technology-led platforms remain intact and differentiated; current softness is timing- and product-mix led, not structural
- Cohance has been awarded EcoVadis Gold, reinforcing governance, compliance, and sustainability credentials

The Company is currently in a transition phase, stabilising leadership and operating teams and progressing toward a steady-state execution model, amid recent management changes and cyclical business downcycles. Organisational capability and customer relevance remain intact.

- Core execution teams across business heads, enabling a clear shift from restructuring to execution
- Recovery is anchored on execution, with focus on RFP conversions, capacity commissioning, and commercial scale-up through Business Development
- FY26 represents a period positioning the organisation for the next growth cycle and management expects a return to revenue growth in FY27

Quality & Governance Focus

- Senior quality leadership embedded, with clear accountability and ownership across sites
- Temporary disruption at Nacharam post OAI and subsequent Warning Letter led to ~₹55 crore shipment deferrals in the period
- Remediation actions are well underway with active regulatory engagement, while all other facilities continue to maintain a strong compliance track record
- OTIF performance consistently above 95% across commercial supplies
- Quality and delivery discipline positioned as structural enablers of future scale-up
- External Advisory Board with globally experienced pharma leaders active, strengthening customer-centric execution and technology-led decision-making

PHARMA CDMO: NAVIGATING NEAR TERM CHALLENGES

- Conversion slower than expected due to customer-led reload delays and payload-intermediate offtake timing, driven by elevated inventories and launch reprioritisation
- Beyond the two de-stocking molecules, some mature commercial products are seeing earlier-than-expected lifecycle / patent-expiry driven volume moderation, contributing to the timing gap
- RFQ intensity 2x YTD; 16+ innovator and biotech audits in last 3–4 months with increased senior customer visits and intent to deepen engagement
- Commercial pipeline: 9 Phase III assets, with 4 expected to move to commercial supply over the coming fiscal; 2 already USFDA-approved/launch phase, 1 priority review, 1 awaiting CY26 readout

ADC AND OLIGOS: LONGER TERM OUTLOOK INTACT

ADC: exclusive payload intermediate supplier to a major innovator; 1 new payload DMF filed and 3 more on track; Vizag business continuity audit completed; USD 10m US-based cGMP expansion underway, enabling ADC supply up to Phase 2b by FY27

Oligonucleotides: Nacharam building-block facility nearing operationalisation; customer qualifications and early commercial engagements progressing as planned; Platform positioned to scale as customer programmes advance into later stages

Subsidiaries/NJ Bio: Customer trial delays and biotech funding cycle impacting renewals; trajectory expected to remain muted into FY27; capacity expansion deferred in line with programme timelines, expected in FY27

SPEC/Ag CHEM PROGRESS IN LINE WITH PLAN

- FY26 impacted by regulatory timing and longer qualification cycles, inherent to the business model; Onboarding of new customers, including Japanese and multinational innovators, continued engagement with a large EU-based agrochemical customer, supports medium-term pipeline visibility
- FY27 expected to remain a transition year, improving as qualifications convert; stronger momentum thereafter

API+ CONTINUES TO TRACK GROWTH

- FY26 shaped by product-level normalisation, including shipment timing and pricing resets in select mature products; Core portfolio stable; diversification supported by newer filings. 8 DMF/CEP filings completed; 5 formulation filings completed
- Nacharam FDF plant issued warning letter from OAI status earlier, related shutdown impacted shipments; Q4 order book healthy; recovery expected into FY27

**BUSINESS AND FINANCIAL
PERFORMANCE**



9MFY26 performance:

- The Revenue increased by 9.3% YoY in 9M adjusting for the de-stocking of the large two commercial products
- Pharma CDMO decline by 12.7% YoY while adjusting for the de-stocking the underlying growth remained in high double digits
- Our Niche technology share continued to be significant contributor with 15.1% share in 9M despite lower ADC payload intermediate revenue contribution in Q3
- Specialty Chemicals revenue reported strong growth of 31.6% YoY, However as we expect delays in regulatory approvals, FY26 revenue growth to be muted
- API+ segment reported decline of 7.9% YoY, due to shipment delays and demand softness in select products and temporary phasing impact related to regulatory remediation at Nacharam formulation plant
- Gross margins improved to 72.8%, up 204 basis points YoY, supported by product mix and the consolidation of subsidiaries
- Adjusted EBITDA for 9MFY26 declined by 43%, with margins at 21.1%. However, standalone Adjusted EBITDA margins stood at 24.2%, highlighting the impact of subsidiary consolidation and muted operating leverage

Sturdy cash generation 9MFY26

- Free cash flow of INR 1.75 Bn generated during the quarter. Cash on books stood at INR 4.32 Bn, maintaining a healthy liquidity position
- INR 1.61 Bn capex deployed, primarily towards Oligo Nacharam facility expansion, Suryapet capacity expansion and some high-containment capabilities upgradations including Parawada, Vizag

Note:

- Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of Rs. 119 mn in 9MFY26 Vs Rs.329 mn in 9MFY25
- Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)

9MFY26 Financial Highlights

(6.7%)

Revenue growth (YoY)

31.6%

Spec Chem growth (YoY)

9.3%

Revenue growth (YoY) excluding de-stocking

INR 16.5 bn

Total Revenue

INR 3.5 bn*

Adjusted EBITDA

INR 1.5 bn*

Adjusted Profit after Tax

21.1%

EBITDA% excl. one time


9.2%

Adjusted PAT %

15.1%

Niche Tech as % of revenue

Segmental Revenue 9MFY26 – CDMO share at 51%



INR mn

Particulars	9MFY25	9MFY26	YoY
Revenue from Operations	17,681	16,494	-6.7%
Material costs / COGS	(5,165)	(4,482)	
Material Margin	12,516	12,012	-4.0%
Material Margin %	70.8%	72.8%	
Manufacturing Expenses	(2,195)	(3,037)	
Employee Cost	(3,093)	(3,787)	
Other Expenses	(1,527)	(1,870)	
Total Expenses	(6,814)	(8,695)	
EBIDTA (Reported)	5,702	3,318	-41.8%
EBIDTA (Reported) %	32.2%	20.1%	
FX MTM gain	117	41	
Onetime expenses	329	119	
EBIDTA (Adjusted)	6,148	3,477	-43.4%
EBIDTA (Adjusted) %	34.8%	21.1%	
Depreciation & Amortization	(1,126)	(1,361)	
Finance costs	(306)	(280)	
Other income	431	284	
PBT (Adjusted before exceptional items)	5,146	2,120	-58.8%
Exceptional Items	0	(130)	
Adjusted PBT	5,146	1,990	
Tax(Adjusted)	(1,229)	(477)	
PAT (Adjusted)	3,917	1,513	-61.4%
PAT Margin %	22.2%	9.2%	
PAT(Reported)	3,669	1597	
PAT Margin %	20.8%	9.7%	

- Adjusting for inventory de-stocking, revenue growth was 9.3% YoY driven by Spec chem and subsidiary consolidation
- Standalone Adjusted EBITDA margins stood at 24.2%, highlighting the impact of subsidiary consolidation and muted operating leverage
- Significant investments continue towards team building and delivering sustainable growth. Concurrently we continue to invest in enhancing our scientific, technical, and commercial capabilities across the platform
- The increase in depreciation cost is largely due to subsidiary consolidation

INR Mn

Balance Sheet Highlights	
As on 31st December 2025	
Shareholders' funds	38,200
Non-Controlling Interests	1,301
Net Fixed assets	35,291
Other net assets ¹	2,451
Net cash/(debt) ²	1,759
Total Use of Funds	39,501

1) Other assets calculated as Inventories + Trade receivables + Non-current investments + Current tax assets + Other assets less Trade payables + deferred tax liabilities + Other liabilities + Forward liability at the end of the period . 2) Net cash/(debt) calculated as the cash & cash equivalents (cash and bank balances + current Investments) less Total debt (Short-term and Long-term borrowings) at the end of the period.

Note:

- 9MFY25 consolidated figures are restated pursuant to Merger and include part period consolidation of NJ BIO (Acquired on 20th Dec-24) and Sapala (Acquired on 11th Jul 24)
- Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of Rs.329 mn in 9MFY25 and 119mn in 9MFY26
- Exceptional item for 9MFY26 Rs.130 Mn represents one-time restructuring costs incurred due to merger of the Company with erstwhile Cohance Lifesciences Limited and actuarial valuation impact of gratuity towards Contract labour (triggerred by new labour code)
- Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)
- PAT(Reported) is after considering Profit/(Loss) attributable to NCI Rs.2 Mn in 9MFY25 and (Rs.179 Mn) in 9MFY26 for Sapala & NJ BIO

INR mn

Particulars	Q3FY25	Q3FY26	YoY
Revenue from Operations	6,762	5,446	-19.5%
Material costs / COGS	(1,888)	(1,589)	
Material Margin	4,874	3,857	-20.9%
Material Margin %	72.1%	70.8%	
Manufacturing Expenses	(795)	(1,020)	
Employee Cost	(1,113)	(1,187)	
Other Expenses	(568)	(681)	
Total Expenses	(2,476)	(2,889)	
EBIDTA (Reported)	2,397	968	-59.6%
EBIDTA (Reported) %	35.5%	17.8%	
FX MTM gain	54	-15	
Onetime expenses	169	-106	
EBIDTA (Adjusted)	2,620	847	-67.7%
EBIDTA (Adjusted) %	38.8%	15.6%	
Depreciation & Amortization	(436)	(469)	
Finance costs	(108)	(91)	
Other income	138	63	
PBT (Adjusted before exceptional items)	2,214	349	-84.2%
Exceptional Items	-	(49)	
Adjusted PBT	2,214	301	
Tax(Adjusted)	(553)	(89)	
PAT (Adjusted)	1,661	211	-87.3%
PAT Margin %	24.6%	3.9%	
PAT(Reported)	1,530	367	
PAT Margin %	22.6%	6.7%	

- Adjusting for inventory de-stocking, revenue declined by 7.0% QoQ reflecting the lumpy nature of commercial drawdowns and shipment timing
- Standalone Adjusted EBITDA margins remained at 19.0%, highlighting the impact of subsidiary consolidation and muted operating leverage
- Significant investments continue towards team building and delivering sustainable growth. Concurrently we continue to invest in enhancing our scientific, technical, and commercial capabilities across the platform

Note:


- Q3FY25 consolidated figures are restated pursuant to Merger and include part period consolidation of NJ BIO (Acquired on 20th Dec-24)
- Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of Rs.169 mn in Q3FY25 and reversal of Rs. 106 mn in Q3FY26
- Exceptional item for Q3FY26 Rs.49 Mn represents actuarial valuation impact of gratuity towards Contract labour(triggered by new labour code)
- Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)
- PAT(Reported) is after considering Profit/(Loss) attributable to NCI Rs.4 Mn in 9MFY25 and (Rs.77Mn) in 9MFY26 for Sapala & NJ BIO

Consolidated Financials


Operational Revenue (INR mn)




Adjusted EBITDA (INR mn) Margin (%)




Adjusted PAT (INR mn) Margin (%)



Pharma CDMO (INR mn)



Agri & Spec Chem (INR mn)



API+ (INR mn)




Due to the lumpy nature of the CDMO Industry, Quarterly comparisons are not reflective of consistent performance

Note:

- Segment revenue's are restated
- Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of Rs.169 mn in Q3FY25 and reversal of Rs. 106 mn in Q3FY26
- Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)

Consolidated Financials



Due to the lumpy nature of the CDMO Industry, Quarterly comparisons are not reflective of consistent performance

- Note:**
- Segment revenue's are restated
 - Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of Rs.329 mn in 9MFY25 and 119mn in 9MFY26
 - Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)

BALANCE SHEET AS ON DECEMBER 31, 2025

INR mn

Balance Sheet Snapshot ¹	FY24	FY25	9MFY26
Property, plant and equipment (PPE) ³	10,649	15,583	17,814
Right of use asset (RoU)	762	2,418	2,307
Capital work-in-progress	4,082	3,316	1,615
Intangible Assets	6,982	13,453	13,555
Net Fixed Assets	22,474	34,770	35,291
Inventories	5,986	4,674	5,994
Trade receivables	6,469	7,721	5,862
Trade payables	(2,418)	(2,684)	(3,138)
Core Net Working Capital (Core NWC)	10,037	9,710	8,717
Other net assets	1,002	(433)	352
Forward Liability	-	(6,519)	(6,618)
Borrowings	(5,274)	(2,584)	(2,560)
Cash and Cash equivalents (including liquid investments)	9,440	2,983	4,319
Net (debt) / cash	4,167	400	1,759
Net assets	37,680	37,929	39,501
Shareholder's funds	37,680	36,488	38,200
Non Controlling Interests		1,441	1,301

Note:

- 1) FY24 Numbers are Proforma numbers for merged entity
- 2) 9MFY26 & FY25 consolidated figures are restated pursuant to Merger
- 3) PPE includes assets held for sale -As per SPA of Sapala Rs.362Mn

- The combined balance sheet remained net cash positive at INR 1.75 bn as of Q3FY26, despite capex and recent acquisitions—underscoring strong internal accruals and disciplined capital deployment
- Strategic investments in capacity expansion across key growth segments and the integration of acquired platforms
- Total borrowings reduced to INR 2.56 Bn, while cash and equivalents stood at INR 4.31 Bn, maintaining healthy liquidity to fund future growth
- Shareholders' equity closed at INR 38.2 Bn, excluding acquisition adjustments, reinforcing a strong capital base as we scale

Key Ratios(Adjusted) [#]	FY24	FY25	9MFY26	Basis
Net Working Capital (as days of sales)	153	136	128	NWC / Revenue * 365 days
PPE (as % of sales)	42.9%	57.2%	69.0%	PPE / Revenue
Capex spend during the year (INR mn)	2,607	3,147	1,611	
Capex spend (as % of sales)	10.9%	12.1%	6.5%	Capex spend / Revenue
(Net Debt)/ Net Cash to adjusted EBITDA (x times)	0.49x	0.05x	0.29x	Net Debt / Adjusted EBITDA
ROCE (%)	30.8%	26.9%	16.1%	Adjusted EBIT / Avg. Capital employed
ROE (%)	21.0%	19.1%	11.2%	Adjusted PAT / Avg Shareholder's funds

Note:

- 1) FY24 Numbers are Proforma numbers for merged entity
- 2) The above ratios for FY25 & 9MFY26 are after considering Sapala and NJBIO consolidation
- 3) Key ratios (Adjusted) are computed on LTM basis considering Net fixed assets, Other net assets and shareholders funds excluding goodwill and fair value changes in assets & liabilities on account of mergers/acquisitions

BUSINESS WISE STRATEGY




Pharma CDMO

39% of Sales



Small Molecules

- **16 Commercial** Patented molecules
- **20/20 Top** innovator relations; contributing >85% revenues
- **9 molecules in Phase-3** translating into 15 intermediates; RFQs growing 2x



ADC* Payload-linker – Bioconjugation

- **Two unique** commercial ADCs payload and intermediate supplies to Large Innovators
- **Expanding payloads portfolio and Clinical Collaborations** – working with other **3** Large Pharma Innovators. Developing new customized payloads and dedicated capacities. Received orders in adjacent payload from EU partner and large Innovator
- **Drug Discovery to commercial** full chain exposure added 17 new customers in CY25 in NJ Bio, including 2 large innovator pharma companies



Oligonucleotides

- Amongst few CDMOs globally specialized in Oligonucleotide and mRNA building blocks including specific delivery systems and Tri-cyclo-DNA
- cGMP on track to be commercially ready; aligned customer audits to validated the plant being scheduled

Specialty Chemicals

12% of Sales



- Strategic Business Unit to focus on growth acceleration by adding new customers and new products
- Dedicated site (Vizag), Available space for future expansion
- Relationships with innovators in AgChem, Electronic Chemicals and Performance coatings
- **AgChem:** relationship strengthening with strategic partner, getting better traction in AIs RFQ
- Good progress with new AgChem partners from Japan and EU
- **Performance Chem:** Relationship with existing partners advancing to next generation products
- Good progress in initiating discussion with other Innovators in similar electronics application

API++

49% of Sales



- Focused portfolio and market leadership in low-mid volume, niche APIs with low competitive intensity
- Ongoing augmentation of new product pipeline
- Built deep cost position through backward integration
- Top 3 player in 8 out of 10 top molecules in the API portfolio
- **Formulation:** : Offering end to end vertically integrated solutions including pellets and formulations for partners
- We have more nearly 50 product families in the APIs and formulation business has nearly 50 ANDAs as partnered and owned put together

Cohance

PHARMA CDMO



MEDIUM TO LONG TERM STRATEGIC APPROACH

Our 30+ year relationships with global innovators and proven expertise in scaling up hazardous chemistry, complex chiral and multi step synthesis offer us a significant and unique advantage.

- **Customer Centricity and Readiness:**

- Customer at the core of all initiatives — delivering reliability, speed, and quality
- Expanded technology base, both organically and inorganically, to support customer programs in complex chemistries (e.g., Flow Chemistry)
- Deepening strategic partnerships with large pharma; leveraging existing networks and the EAB to accelerate growth in the next 12–18 months
- Partnering with select biotech innovators on emerging modalities to stay ahead of technological advancements

- **Strengthening our tech modalities**

- ADC & Oligo: Cross-sell within existing customer base and acquire new customers through niche modalities
- Expand Flow Chemistry and Peptide capabilities organically and inorganically over the next 12–24 months


- **Quality of RFP and conversions**

- Continue to diversify the customer base from our strategic relationship to get high quality RFPs and improve conversions (specifically laterals)

- **Strong Process R&D capability for speed, Quality and continuous improvement**

- **Execution & Capacity Expansion to deliver on time**


- Strong Quality track record in US FDA approved sites in CDMO business
- Expand capacities and improve assets for our customers (eg new capacity)




Small Molecules

- Near-term revenues impacted by customer-led delays in reloads and payload-intermediate offtake, driven by high inventories and launch reprioritisation
- Additional impact from earlier-than-expected volume moderation in select mature commercial products nearing late lifecycle / patent expiry
- **Strong customer engagement:**
 - RFQ intensity up ~2x YTD
 - 16+ large & mid-pharma / biotech audits/visits in last 3-4 months; high level delegation
 - Visibly increasing senior-level customer visits and intent to deepen engagements
- **Commercial pipeline progressing:**
 - 9 Phase III molecules supported
 - 4 expected to enter commercial supply over next 12–18 months
 - 2 with USFDA approval (initial launch phase)
 - 1 under USFDA Priority Review
 - 1 awaiting data readout in CY26
- **First** conversion from the pending RFPs- **commercial product** from a large US customer.
- Another commercial KSM programme won from an EU partner.
- Onboarded additional large Japanese customers; biotech engagement continues to deepen

Phase III pipeline



RFQs Inflow



ADC AND OLIGOS: LONGER TERM OUTLOOK INTACT

ADC

Near-term demand influenced by biotech funding cycles, though customer programmes remain active

Exclusive payload intermediate supplier to a major innovator

One new ADC payload DMF filed; three additional payload filings progressing as planned

USD 10m US-based cGMP expansion underway, enabling ADC supply up to Phase 2b by FY27

Business continuity audit at Vizag site completed successfully, supporting customer confidence

Oligonucleotides

cGMP oligonucleotide building-block facility at Nacharam nearing operationalisation

Customer qualifications and early commercial engagements progressing as planned

Platform positioned to scale as customer programmes advance into later stages

Oligonucleotides
market to grow at
25%+ CAGR



MARKET LEADERS



SN-38


Exatecan

DXd

Other known CPT derivatives

Novel CPT derivatives

104+ Clinically Active Compounds
Jan 2025



Cohance

API+





Near-term moderation driven by shipment timing adjustments and pricing normalisation in select mature products

Core products and newer filings continue to provide diversification and sustainable growth pipeline

DMF & CEP filings on track:

- 8 filings completed (API)
- 5 formulation filings completed

Nacharam FDF facility stabilised post OAI-WL-related shutdown; operations resumed in phase manner for non-US markets, with higher capacity post CAPA implementation

Q4 order book healthy; recovery expected to be gradual into FY27

Cohance

SPECIALTY CHEMICAL



FY26 impacted by regulatory timing and longer qualification cycles, inherent to the business model

Continued engagement with a large EU-based agrochemical customer, supporting medium-term pipeline visibility

Two new customers onboarded during the year, including Japanese and multinational innovators. The Japanese customer's commercial qualification campaign expected to go by the end of FY27E

Strengthening R&D and process intensification to handle more value-added, and complex chemistries. We are working towards extending our core chemistry platforms into semiconductor chip processing

FY27 expected to remain a transition year, with improvement as qualifications convert

ANNEXURES



We have set multi-dimensional ESG goals

Our achievement



Achieved **B** rating in Climate Change and **A-** Water in 2025



Gold in EcoVadis Sustainability assessment for Cohance.



* Targets have been **approved** by SBTi for Suven sites



Pharmaceutical Supply Chain Initiative (PSCI) **Supplier Partner** – 2025




UNGC - Yearly CEO commitments given to implement universal sustainability principles



97% score in TFS audit



British Safety Council's International Safety Awards (ISA) 2025.



ESG Profile



Up coming milestones



Platinum in Eco Vadis Sustainability assessment – 2026



Signing third party purchase agreement for renewable power for all the facilities




SBTi combined entity targets to be submitted for approval-2026.



British safety council **five-star** certification and sword of honor-2026

*Note: The current targets are based on Cohance (erstwhile Suven's) approved SBTi targets and combined ESG report. These will be revised once the consolidated ESG report is published and SBTi targets for the merged entity are approved.

*Baseline Year FY 2022-23



Expanded and strengthened Business Development, Quality & R&D functions

R&D function bolstered with large number of PhD additions

Onboarded Plant Heads & Regional Business Managers

All CXO positions in place

Most new hires from leading Indian pharma companies

Established processes and systems to optimize decision making and opportunity identification

Lab & Kilo scale

Pilot and Commercial scale (~3,000+ kL capacity)

Pharma CDMO



Genome valley, Hyderabad



Nacharam, Hyderabad (Oligo CoE)



Princeton, New Jersey



Suryapet, Telangana




Jeedimetla, Hyderabad



Pashamylaram, Hyderabad



Vizag, Andhra Pradesh



Nacharam, Hyderabad

API+



Patancheru, Hyderabad



Atchutapuram, Andhra Pradesh



Jaggaihpeta, Andhra Pradesh



Ankleshwar, Gujarat



Jadcherla, Telangana

Spec Chem



Genome valley, Hyderabad



Vizag, Andhra Pradesh



Vizag, Andhra Pradesh

FDF



Nacharam, Hyderabad



Pashamylaram-R&D, Hyderabad



Pashamylaram, Hyderabad



Casper Pharma, Hyderabad



Nacharam, Hyderabad



US FDA Audited site

Cyndrella Carvalho, Head - Investor Relations
Cohance Lifesciences Ltd

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar
CDR - India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com / rishab@cdr-india.com



Cohance



THANK YOU